Abstract #4000

MET陽性の進行胃癌/食道胃接合部癌に対する1st-line治療としてのRilotumumab + Epirubicin, Cisplatin, Capecitabine (ECX) 療法の多施設共同プラセボ対照二重盲検無作為化第III相試験：RILOMET-1試験

Phase III, Randomized, Double-blind, Multicenter, Placebo-controlled Trial of Rilotumumab Plus Epirubicin, Cisplatin, and Capecitabine as 1st-line Therapy in Patients with Advanced MET-positive Gastric or Gastroesophageal Junction Cancer: RILOMET-1 Study

David Cunningham, et al.

Abstract #4001

進行胃癌に対する抗PD-1モノクローナル抗体薬Pembrolizumab (MK-3475) におけるPD-L1の発現と予後の関連性について：KEYNOTE-012試験

Relationship between PD-L1 Expression and Clinical Outcomes in Patients with Advanced Gastric Cancer Treated with the Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) in KEYNOTE-012

Yung-Jue Bang, et al.

Abstract #4003

化学療法不応後の進行食道胃腺癌に対するRegorafenibのプラセボ比較無作為化第II相試験 (INTEGRATE)

INTEGRATE: A Randomized, Phase II, Double-blind, Placebo-controlled Study of Regorafenib in Refractory Advanced Oesophagogastric Cancer (AOGC): A Study by the Australasian Gastrointestinal Trials Group (AGITG) Final Overall and Subgroup Results

Nick Pavlakis, et al.

Abstract #4004

SWOG S0518：進行性予後不良カルチノイド患者に対するOctreotide + Interferon (IFN) α-2bとOctreotide + Bevacizumabの前向き無作為化第III相比較試験

SWOG S0518: Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha-2b Versus Depot Octreotide Plus Bevacizumab in Advanced, Poor Prognosis Carcinoid Patients

James C. Yao, et al.

Abstract #4006

ヒアルロン酸高値の進行再発膵癌に対するnab-Paclitaxel / GemcitabineへのPEGPH20上乗せ効果の検討：無作為化第II相試験の中間解析

High Response Rate and PFS with PEGPH20 Added to Nab-Paclitaxel / Gemcitabine in Stage IV Previously Untreated Pancreatic Cancer Patients with High-HA Tumors: Interim Results of a Randomized Phase 2 Study

Sunil Hingorani, et al.

Abstract #4010

進行食道癌に対するPembrolizumab (MK-3475) ：KEYNOTE-028試験の中間報告

Pembrolizumab (MK-3475) for Patients with Advanced Esophageal Carcinoma: Preliminary Results from KEYNOTE-028

Toshihiko Doi, et al.